CLIMARA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CLIMARA (CLIMARA).
Estradiol replacement therapy; binds to estrogen receptors, activating gene transcription leading to estrogenic effects in target tissues.
| Metabolism | Hepatic via CYP3A4; also undergoes conjugation (glucuronidation, sulfation). |
| Excretion | Renal: 70-80% as glucuronide and sulfate conjugates; biliary/fecal: 20-30%. |
| Half-life | Terminal elimination half-life is approximately 13–17 hours for estradiol via transdermal route, supporting once-weekly dosing. |
| Protein binding | Approximately 98% bound, primarily to sex hormone-binding globulin (SHBG) and albumin. |
| Volume of Distribution | Apparent Vd is about 1.5–2.0 L/kg, reflecting extensive distribution and tissue binding. |
| Bioavailability | Transdermal: Approximately 10–20% of the nominal dose delivered, bypassing first-pass metabolism; absolute bioavailability compared to oral is about 100% for absorbed dose. |
| Onset of Action | Transdermal: Therapeutic serum estradiol levels achieved within 4–8 hours; steady-state reached after 2–3 applications. |
| Duration of Action | 7 days per patch. Clinical effect maintained for 7 days with steady serum levels; patch replacement recommended every 7 days. |
| Molecular Weight | 272.38 |
Transdermal, 0.025-0.1 mg/day applied once weekly; start with lowest effective dose. Adjust based on clinical response.
| Dosage form | FILM, EXTENDED RELEASE |
| Renal impairment | No dose adjustment required for renal impairment; use with caution in severe impairment. |
| Liver impairment | Contraindicated in severe hepatic disease (Child-Pugh class C). In mild to moderate hepatic impairment, use with caution and monitor liver function; reduce dose if needed. |
| Pediatric use | Not recommended for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | Initiate at lowest effective dose (0.025 mg/day); consider risk of thromboembolic events and malignancy; monitor closely. |
| 1st trimester | Estradiol is contraindicated in pregnancy due to risk of fetal harm. Animal studies show teratogenic effects; human data insufficient but potential for urogenital tract abnormalities. |
| 2nd trimester | Use is contraindicated; estradiol may cause adverse fetal effects including possible cardiovascular and limb defects. |
| 3rd trimester | Use is contraindicated; estradiol may delay labor and cause neonatal withdrawal symptoms. |
Clinical note
Comprehensive clinical and safety monograph for CLIMARA (CLIMARA).
| Placental transfer | Estradiol crosses the placenta readily; placental transfer is significant. |
| Breastfeeding | Estradiol is excreted in human milk in low amounts. It may reduce milk production and quality. Use with caution in nursing mothers only if clearly needed. |
■ FDA Black Box Warning
Estrogens should not be used to prevent cardiovascular disease or dementia. Increased risk of endometrial cancer, stroke, deep vein thrombosis, pulmonary embolism, myocardial infarction, and breast cancer.
| Serious Effects |
Known or suspected pregnancyUndiagnosed abnormal genital bleedingKnown, suspected, or history of breast cancerKnown or suspected estrogen-dependent neoplasiaActive or history of venous thromboembolismActive or history of arterial thromboembolismKnown protein C, protein S, or antithrombin deficiencyHepatic impairment or diseaseHypersensitivity to estradiol or any component
| Precautions | Increased risk of endometrial cancer (use progestin if uterus intact), cardiovascular disorders, thromboembolism, gallbladder disease, hypercalcemia, visual abnormalities, and hereditary angioedema. Should be used at the lowest effective dose for shortest duration. |
| Food/Dietary | No specific food interactions. Grapefruit juice may slightly increase estrogen levels but clinical significance is minimal. Avoid excessive alcohol consumption as it may increase risk of adverse effects. Maintain adequate calcium and vitamin D intake for bone health. |
Loading safety data…
| Lactation Rating |
| L3 (Moderately Safe) |
| Teratogenic Risk | Pregnancy Category X. Use of estrogen-containing products, including Climara (estradiol transdermal system), is contraindicated during pregnancy. Estrogens are known to cause fetal harm when administered to pregnant women. First trimester exposure has been associated with an increased risk of congenital anomalies, particularly cardiovascular and central nervous system defects. Second and third trimester exposure may lead to urogenital abnormalities and other reproductive tract anomalies in female offspring, as well as potential long-term neurodevelopmental effects. The drug should not be used during pregnancy; if pregnancy occurs, therapy should be discontinued immediately. |
| Fetal Monitoring | In the rare event of accidental exposure during pregnancy, fetal monitoring is not specifically indicated for estrogen exposure. However, pregnancy should be confirmed negative before initiating therapy. Routine prenatal care with ultrasound to assess fetal anatomy is recommended if exposure occurs. No specific maternal monitoring beyond standard obstetric care is required. |
| Fertility Effects | Climara may suppress ovulation through negative feedback on gonadotropin secretion, potentially impairing fertility. When used as hormone replacement therapy, it is not indicated for contraception. Rebound ovulation may occur after discontinuation. In women of reproductive potential, effective non-hormonal contraception should be used during therapy. |
| Clinical Pearls | Climara is a transdermal estradiol patch used for menopausal hormone therapy. Apply to clean, dry, non-irritated skin on lower abdomen or upper buttock; avoid oily or damaged skin. Rotate application sites to minimize local reactions. Do not apply to breasts or waistline. Patches should be changed twice weekly (every 3-4 days). Monitor for signs of thrombosis, gallbladder disease, and endometrial cancer. Use lowest effective dose for shortest duration. |
| Patient Advice | Apply the patch to clean, dry skin on the lower abdomen or upper buttock; do not apply to breasts or waistline. · Change the patch every 3 to 4 days (twice weekly); remove old patch before applying new one. · Rotate application sites to reduce skin irritation. · Do not expose the patch to direct heat sources (heating pads, saunas) as it may increase absorption. · If the patch falls off, reapply a new one and maintain the same schedule. · Report signs of blood clots (sudden chest pain, shortness of breath, leg pain/swelling), jaundice, or abnormal vaginal bleeding immediately. · Avoid smoking as it increases risk of cardiovascular side effects. · Keep the patch out of reach of children and pets; used patches still contain active hormone. |